In previous clinical trials, Li et al. (2013) and Chen et al. (2013) reported that the combination of Bifidobacterium quadruple viable tablets and antihistamines could significantly reduce the serum IL-10 level and increase the serum IFN-γ level in patients with urticaria, supporting our findings. The gene discussed is IL10; the disease is urticaria.